Pubblicazioni

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice

2019 - ANNALS OF HEMATOLOGY

Scalzulli, Emilia; Molica, Matteo; ALUNNI FEGATELLI, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; FoÃ &, Robin; Breccia, Massimo

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes. a âGruppo Romano Mielodisplasie (GROM)â multicenter study

2016 - ANNALS OF HEMATOLOGY

Buccisano, Francesco; Piccioni, Anna Lina; Nobile, Carolina; Criscuolo, Marianna; Niscola, Pasquale; Tatarelli, Caterina; Fianchi, Luana; VillivÃ , Nicoletta; Neri, Benedetta; Carmosino, Ida; Gumenyuk, Svitlana; Mancini, Stefano; Voso, Maria Teresa; Maurillo, Luca; Breccia, Massimo; Zini, Gina; Venditti, Adriano; Fenu, Susanna; Spiriti, Maria Antonietta Aloe; Latagliata, Roberto

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

2015 - ANNALS OF HEMATOLOGY

Breccia, M; Voso, Mt; ALOE SPIRITI, Maria Antonietta; Fenu, S; Maurillo, L; Buccisano, F; Tafuri, Agostino; Alimena, Giuliana

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies